Stanford University Cancer Center

斯坦福大学癌症中心正在向国家癌症研究所（NCI）申请为期五年的资助， 癌症中心支持补助金（CCSG）和指定为综合癌症中心。过去 三年来，癌症中心已经从260名成员发展到311名成员，代表了四所学校。 斯坦福大学（医学、工程、人文科学和法律）和北方加州 癌症中心与斯坦福大学有着长期的，科学上富有成效的关系， 正式加盟协议。 CCSG的建议建立在技术开发的机构优势之上，特别是在以下领域： 成像、生物技术、信息学和化学工程。这些研究领域的整合 进入癌症生物学、免疫学、遗传学和干细胞生物学领域，开发新的 癌症预防、诊断和治疗的方法是该癌症中心的特色。 10个项目涵盖癌症的基础、转化/临床和人口科学研究领域 （癌症生物学，放射生物学，癌症干细胞，癌症成像和早期检测，分子 治疗学，淋巴瘤和霍奇金病，癌症免疫学和免疫疗法，造血 细胞移植和免疫重建，癌症流行病学和癌症预防， 对照）。十一个共享资源支持进行的基础和转化/临床研究 在中心。 基于目前NCI基础资金3600万美元，其他NIH支持5800万美元， 在其他同行评审的癌症相关资金中，该中心要求530万美元的直接费用， 支持其活动。随着两座用于基础研究和转化研究的新建筑的出现， 招聘，并增加合作互动，该中心准备作出重大贡献 在新的资助期内进行癌症研究。

The Stanford Cancer Center is applying to the National Cancer Institute (NCI) for five years of funding of a Cancer Center Support Grant (CCSG) and for designation as a Comprehensive Cancer Center. Over the past three years, the Cancer Center has grown from 260 to 311 members representing four Schools within Stanford University (Medicine, Engineering, Humanities and Sciences and Law) and the Northern California Cancer Center with which Stanford has had a long-standing, scientifically productive relationship under a formal affiliation agreement. The CCSG proposal is built upon institutional strengths in technology development, particularly in the fields of imaging, biotechnology, informatics, and chemical engineering. The integration of these research areas into the fields of cancer biology, immunology, genetics and stem cell biology in the development of new approaches to cancer prevention, diagnosis and treatment is the distinguishing feature of this Cancer Center. Ten programs cover the areas of basic, translational/clinical, and population science research in cancer (Cancer Biology, Radiation Biology, Cancer Stem Cells, Cancer Imaging and Early Detection, Molecular Therapeutics, Lymphoma and Hodgkin Disease, Cancer Immunology and Immunotherapy, Hematopoietic Cell Transplantation and Immune Reconstitution, Cancer Epidemiology, and Cancer Prevention and Control). Eleven Shared Resources support the basic and translational/clinical investigation that is carried out in the Center. Based on current NCI base funding of $36 million and with $58 million in other NIH support and $16 million in other peer-reviewed cancer-relevant funding, the Center is requesting $5.3 million in direct costs to support its activities. With the advent of two new buildings for basic and translational research, new recruitment, and increased collaborative interactions, the Center is poised to make significant contributions to cancer research in the new funding period.